<DOC>
	<DOC>NCT00500292</DOC>
	<brief_summary>The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.</brief_summary>
	<brief_title>A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Progression on or following treatment for metastatic colorectal cancer Have failed therapy with an irinotecan and fluoropyrimidine containing regimen Have World Health Organisation (WHO) performance status 02 and life expectancy &gt;12 weeks Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR Prior monoclonal antibodies are permitted, (eg, cetuximab, bevacizumab) Previous adjuvant therapy with irinotecan within 12 months of randomisation More than one prior course of chemotherapy for treatment of metastatic colorectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>zactima</keyword>
</DOC>